Published in J Neurol on April 06, 2007
Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes. J Neural Transm (Vienna) (2011) 1.19
Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration. Biomed Res Int (2014) 1.00
Hyperechogenicity of the substantia nigra: pitfalls in assessment and specificity for Parkinson's disease. J Neural Transm (Vienna) (2010) 0.91
Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound. Ultrasound Med Biol (2010) 0.84
Major Alterations of Phosphatidylcholine and Lysophosphotidylcholine Lipids in the Substantia Nigra Using an Early Stage Model of Parkinson's Disease. Int J Mol Sci (2015) 0.79
Substantia nigra hyperechogenicity with LRRK2 G2019S mutations. Mov Disord (2011) 0.78
Brain Iron Metabolism Dysfunction in Parkinson's Disease. Mol Neurobiol (2016) 0.77
Parkinson's Disease: The Mitochondria-Iron Link. Parkinsons Dis (2016) 0.76
Molecular pathways of neurodegeneration in Parkinson's disease. Science (2003) 7.55
The effect of age on the non-haemin iron in the human brain. J Neurochem (1958) 4.83
Early-onset parkinsonism associated with PINK1 mutations: frequency, genotypes, and phenotypes. Neurology (2005) 2.69
Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol (2005) 2.54
Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function. Hum Mol Genet (2005) 1.58
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol (2002) 1.45
Transgenic models of alpha-synuclein pathology: past, present, and future. Ann N Y Acad Sci (2003) 1.36
Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings. J Neurol (2001) 1.27
Case-control study of the parkin gene in early-onset Parkinson disease. Arch Neurol (2006) 1.26
In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord (2005) 1.23
Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat (2004) 1.22
Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord (2005) 1.19
Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology (2004) 1.03
Iron and Parkinson's disease. Neuroscientist (2002) 0.97
Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord (2004) 0.88
Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Adv Neurol (1993) 0.88
Parkin gene variations in late-onset Parkinson's disease: comparison between Norwegian and German cohorts. Acta Neurol Scand (2006) 0.80
Autosomal recessive juvenile parkinsonism Cys212Tyr mutation in parkin renders lymphocytes susceptible to dopamine- and iron-mediated apoptosis. Mov Disord (2004) 0.80
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat Genet (2009) 10.34
Mortality after surgery in Europe: a 7 day cohort study. Lancet (2012) 9.96
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet (2011) 9.10
Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. J Am Soc Nephrol (2004) 7.79
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (2012) 6.61
Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J Neurosci (2007) 5.68
SAPS 3--From evaluation of the patient to evaluation of the intensive care unit. Part 2: Development of a prognostic model for hospital mortality at ICU admission. Intensive Care Med (2005) 4.66
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA (2006) 4.26
Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol (2004) 3.83
SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol (2009) 3.55
Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. Intensive Care Med (2009) 3.20
A draft genome of Yersinia pestis from victims of the Black Death. Nature (2011) 3.18
Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol (2011) 3.01
SAPS 3--From evaluation of the patient to evaluation of the intensive care unit. Part 1: Objectives, methods and cohort description. Intensive Care Med (2005) 2.84
Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J (2004) 2.78
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet (2005) 2.59
Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med (2008) 2.51
Errors in administration of parenteral drugs in intensive care units: multinational prospective study. BMJ (2009) 2.46
The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study. Lancet Neurol (2008) 2.42
PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain (2005) 2.40
Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann Neurol (2005) 2.40
A multicenter study of glucocerebrosidase mutations in dementia with Lewy bodies. JAMA Neurol (2013) 2.32
Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet (2005) 2.28
Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurol (2013) 2.24
Olfactory dysfunction: common in later life and early warning of neurodegenerative disease. Dtsch Arztebl Int (2013) 2.22
Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell (2013) 2.22
Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol (2009) 2.21
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia. Mov Disord (2008) 2.15
Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study. J Clin Psychiatry (2009) 2.09
Variability in outcome and resource use in intensive care units. Intensive Care Med (2007) 2.04
Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann Neurol (2008) 2.04
Incidence and prognosis of dysnatremias present on ICU admission. Intensive Care Med (2009) 1.97
Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain. FASEB J (2007) 1.94
The German hospital malnutrition study. Clin Nutr (2006) 1.93
Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol (2006) 1.92
Epidemiology of mechanical ventilation: analysis of the SAPS 3 database. Intensive Care Med (2009) 1.88
Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet (2010) 1.86
Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain (2005) 1.85
Impact of body mass on incidence and prognosis of acute kidney injury requiring renal replacement therapy. Intensive Care Med (2010) 1.83
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Genome-wide comparison of medieval and modern Mycobacterium leprae. Science (2013) 1.81
Testing and estimation in flexible group sequential designs with adaptive treatment selection. Stat Med (2005) 1.80
Parkinson patient fibroblasts show increased alpha-synuclein expression. Exp Neurol (2008) 1.79
DJ-1 and prevention of oxidative stress in Parkinson's disease and other age-related disorders. Free Radic Biol Med (2009) 1.78
Red flags for multiple system atrophy. Mov Disord (2008) 1.75
Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res (2012) 1.74
Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet (2011) 1.70
PARK6-linked parkinsonism occurs in several European families. Ann Neurol (2002) 1.68
Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Hum Mol Genet (2012) 1.68
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PLoS One (2010) 1.62
End-of-life practices in 282 intensive care units: data from the SAPS 3 database. Intensive Care Med (2008) 1.62
Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol (2011) 1.62
GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest (2008) 1.60
Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair. Hum Mol Genet (2009) 1.59
Kick and rush: paradoxical kinesia in Parkinson disease. Neurology (2008) 1.59
Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. Eur Heart J (2004) 1.58
Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol (2009) 1.58
Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet (2006) 1.56
UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol (2004) 1.54
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord (2005) 1.54
GBA-associated PD. Neurodegeneration, altered membrane metabolism, and lack of energy failure. Neurology (2012) 1.51
Poor effect of guideline based treatment of restless legs syndrome in clinical practice. J Neurol Neurosurg Psychiatry (2010) 1.49